Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma
- PMID: 15240545
- DOI: 10.1158/1078-0432.CCR-04-0194
Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma
Abstract
Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth.
Experimental design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR).
Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined.
Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.
Similar articles
-
Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.Clin Cancer Res. 2005 Jul 1;11(13):4934-40. doi: 10.1158/1078-0432.CCR-04-2270. Clin Cancer Res. 2005. PMID: 16000592
-
Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2.Cancer Res. 2001 Dec 15;61(24):8730-6. Cancer Res. 2001. PMID: 11751392
-
Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors.Clin Cancer Res. 2002 Nov;8(11):3539-48. Clin Cancer Res. 2002. PMID: 12429645
-
Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system.Biochem Pharmacol. 2004 Sep 15;68(6):1017-21. doi: 10.1016/j.bcp.2004.05.030. Biochem Pharmacol. 2004. PMID: 15313395 Review.
-
Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion.Cell Tissue Res. 2002 Dec;310(3):257-70. doi: 10.1007/s00441-002-0651-7. Epub 2002 Nov 6. Cell Tissue Res. 2002. PMID: 12457224 Review.
Cited by
-
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.Br J Cancer. 2010 Sep 7;103(6):827-36. doi: 10.1038/sj.bjc.6605832. Epub 2010 Aug 24. Br J Cancer. 2010. PMID: 20736949 Free PMC article.
-
Design and synthesis of C-terminal modified cyclic peptides as VEGFR1 antagonists.Molecules. 2014 Sep 26;19(10):15391-407. doi: 10.3390/molecules191015391. Molecules. 2014. PMID: 25264829 Free PMC article.
-
Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma.PLoS One. 2015 Jun 10;10(6):e0129433. doi: 10.1371/journal.pone.0129433. eCollection 2015. PLoS One. 2015. PMID: 26061425 Free PMC article.
-
The role of the extracellular matrix in angiogenesis in malignant glioma tumors.Brain Pathol. 2005 Oct;15(4):318-26. doi: 10.1111/j.1750-3639.2005.tb00117.x. Brain Pathol. 2005. PMID: 16389944 Free PMC article. Review.
-
Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions.Pharm Res. 2005 Aug;22(8):1411-21. doi: 10.1007/s11095-005-5265-9. Epub 2005 Aug 3. Pharm Res. 2005. PMID: 16078152
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical